Antigen Presenting Cell News Today

COPENHAGEN, Denmark, May 16, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development

COPENHAGEN, Denmark, May 16, 2023 -- Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announced that... | May 16, 2023

Q1 Presentation May 12, 2023 Forward-looking statement ... | May 12, 2023

VB10.16 Final Phase 2 data readout - 12 month treatment follow up April 19 2023 ... | April 19, 2023

Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in ImmunologyContinued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company’s Point-of-Care SystemAnticipate Interim...

Graft-versus-host disease (GVHD) is a major complication that occurs following allogeneic haematopoietic stem cell transplantation (HSCT) for the treatment of haematological cancers and other blood-related disorders. GVHD is an inflammatory disorder, where the transplanted donor immune cells can mediate an immune response against the recipient and attack host tissues. Despite over 60 years of research, broad-range immune suppression is still used to prevent or treat GVHD, leading to an increased...

Granted FDA Fast Track Designation for APC Clinical CandidatePublished Comprehensive Preclinical Research on SQZ® TAC Platform in Frontiers in ImmunologyPresented First SQZ® Point-of-Care (POC) Manufacturing System Performance Data; Initial Clinical Use Planned for SQZ® TAC Celiac Disease Program with IND Submission...

ESMO Immuno-Oncology and Technology Article Details Importance of Intracellular Delivery to Drive Effective MHC-I Mediated Activation of CD8 T CellsPaper Highlights Preclinical SQZ® APC Combination Data with PD-1 IL2v and Manufacturing Benefits of the Cell Squeeze® TechnologyWATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Bi...

Investegate announcements from Evaxion Biotech, Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

 Granted FDA Fast Track Designation for Lead APC Clinical CandidateReceived FDA IND Clearance to Initiate Phase 1/2 Clinical Trial of Next Generation eAPC Therapeutic Candidate for HPV16+ Solid TumorsPublished Peer Reviewed, Comprehensive Preclinical Research Supporting SQZ® APC and TAC Therapeutic ProgramsAnticipat...